In 2019 Prof Andrew Tobin published validation of PfCLK3 as a target with breakthrough potential in the treatment of malaria. Successful drug development would provide a single medicine that is curative, transmission blocking and prophylactic.
Together the KELTICPharma team combine academic innovation, deep target knowledge and corporate drug discovery expertise.
Generating next generation anti-malarials.
KELTICPharma Therapeutics founders have extensive experience in the malaria field particularly in the biochemical processes that are essential for parasite survival.
By identification of essential pathways the founders have established that a particular protein kinase called PfCLK3, when inhibited can not only kill the blood stage of the malaria parasite but also kill liver stage and prevent development through the sexual stages. In this way inhibitors to PfCLK3 can offer a cure, prophylaxis and a block of transmission.
The molecular parasitology and chemistry expertise with KELTICPharma Therapeutics and our collaborators are now pursing inhibition of PfCLK3 in a drug discovery program aimed at generating next generation anti-malarials.
Generating Receptor-Based Medicines
The Founders of KELTICPharma Therapeutics have decades of research experience in a class of cell surface receptor called G protein coupled receptors (GPCRs). This class of receptor are the worlds most successful drug targets. However despite this success the full potential of GPCRs as drug target has yet to be fully released.
A subclass of GPCRs have been classified as ‘hard to target’ due to the ligand binding pocket being shallow and poorly defined.
KELTICPharma Therapeutics a founders have invented a novel drug discovery platform called PEP-SMOL that is specifically designed to generate small drug-like molecule hits against shallow binding pockets.
By deploying PEP-SMOL – KELTICPharma Therapeutics will pursue drug discovery programs against high value GPCR targets that previously have been considered either ‘hard to target’ or even ‘un-druggable’.
Job Opportunity 1
Role: Parasitologist Research Scientist
Location: Glasgow, UK
Apply to recruitment@kelticpharmatherapeutics.com
Closing Date: Dec 1st 2021
We have an exciting new opportunity for a highly motivated Research Scientist to build their career in our Discovery Team based in Glasgow. The successful candidate will be responsible for completing P. falciparum culture assays to deliver robust data packages that characterise compounds and peptides. The role will provide opportunity to develop skills associated with running, developing and improving medium through-put parasite assays whilst establishing the applicant in a dynamic and diverse industry setting.
Job Opportunity 2
Role: Peptide Phage Display Scientist
Location: Glasgow, UK
Apply to recruitment@kelticpharmatherapeutics.com
Closing Date: Dec 1st 2021
We have an exciting new opportunity for a highly skilled Research Scientist. We are seeking an experienced, versatile, and self-driven senior scientist who has excellent knowledge and understanding of peptide phage display with exceptional practical ability to support delivery of our in-house drug discovery programs. In this role you will lead, design, and conduct experiments, develop methods, interpret and report scientific data. You will be a proven problem solver, have exceptional communication skills and be a team player. This role will be essential for solving specific scientific questions at all stages of the Keltic Pharma Therapeutics pipeline, from initial target validation and protein QC, screening, and through to supporting assays and to developing drug molecules.
Founder
Founder
Founder
Founder
GU Holdings Ltd.
By Email
General Enquiries
info@kelticpharmatherapeutics.com
Recruitment
recruitment@kelticpharmatherapeutics.com
By Post
KELTIC Pharma Therapeutics Ltd
27 Upper Pembroke Street
Dublin 2
Ireland
